Phospho-CHEK2 (Thr387) Antibody

What is Phospho-CHEK2 (Thr387) Antibody and what is its specificity?

Phospho-CHEK2 (Thr387) antibody is a specialized immunological reagent designed to detect endogenous levels of the CHEK2 protein specifically when it is phosphorylated at threonine 387. These antibodies are typically developed using synthesized peptides derived from human CHEK2 around the phosphorylation site of Thr387 as immunogens . The antibodies undergo affinity purification via sequential chromatography on phospho- and non-phospho-peptide affinity columns to ensure high specificity .

The specificity of these antibodies is critically important for research applications, as they do not recognize unphosphorylated CHEK2 or CHEK2 phosphorylated at other sites. This selective recognition enables researchers to monitor the activation state of CHEK2 kinase in response to various stimuli, particularly DNA damage .

What is the biological significance of CHEK2 Thr387 phosphorylation?

CHEK2 (Checkpoint Kinase 2) is a serine/threonine kinase that functions as a critical component of the DNA damage response pathway. Phosphorylation at Thr387 is an important activation marker for CHEK2 kinase activity and represents a key regulatory event in the cellular response to DNA damage, particularly double-strand breaks .

When DNA damage occurs, CHEK2 undergoes a series of phosphorylation events, including at Thr387, which activates its kinase activity. Once activated, CHEK2 phosphorylates downstream substrates including:

• CDC25C phosphatase, preventing entry into mitosis

• p53, leading to cell cycle arrest in G1

• BRCA1, enabling DNA repair and survival after damage

This phosphorylation cascade is essential for halting cell cycle progression, allowing time for DNA repair or, if damage is too severe, triggering apoptosis. Dysregulation of this pathway is linked to genomic instability and cancer development .

What are the main applications of Phospho-CHEK2 (Thr387) Antibody in research?

Phospho-CHEK2 (Thr387) antibodies are versatile tools with several key applications in research:

• Western Blotting (WB): Typically used at dilutions of 1:500-1:2000, these antibodies allow detection of phosphorylated CHEK2 in cell or tissue lysates. Western blotting can reveal changes in CHEK2 phosphorylation status following various treatments or in different cell types .

• Immunohistochemistry (IHC): At dilutions of 1:50-1:300, these antibodies can detect phosphorylated CHEK2 in fixed tissue sections, enabling visualization of CHEK2 activation patterns in different tissues or disease states .

• Immunofluorescence/Immunocytochemistry (IF/ICC): Used at dilutions of 1:50-1:500, these applications allow subcellular localization studies of phosphorylated CHEK2 .

• ELISA: These antibodies can be used in enzyme-linked immunosorbent assays for quantitative determination of phosphorylated CHEK2 levels .

• Cell-Based ELISA: Specialized kits enable detection of CHEK2 phosphorylation directly in cultured cells without the need for cell lysis, providing a high-throughput approach for screening compounds that affect CHEK2 activation .

These applications collectively enable researchers to investigate CHEK2 activation across diverse experimental contexts.

What species reactivity can I expect with Phospho-CHEK2 (Thr387) antibodies?

Most commercially available Phospho-CHEK2 (Thr387) antibodies demonstrate confirmed reactivity with human, mouse, and rat samples . This cross-species reactivity reflects the evolutionary conservation of the CHEK2 phosphorylation site across mammals.

Some antibodies also have predicted reactivity with additional species including pig, zebrafish, bovine, horse, sheep, rabbit, dog, chicken, and Xenopus, although these predictions may require validation in specific research contexts . When working with less common experimental models, it is advisable to perform preliminary validation studies to confirm antibody reactivity.

The broad species reactivity makes these antibodies valuable tools for comparative studies across different model organisms, facilitating translational research from animal models to human applications.

How can I validate the specificity of Phospho-CHEK2 (Thr387) Antibody in my experimental system?

Validating antibody specificity is critical for generating reliable data. For Phospho-CHEK2 (Thr387) antibodies, consider these validation approaches:

• Phosphatase Treatment: Treating one sample with lambda phosphatase before immunoblotting should eliminate the signal if the antibody is truly phospho-specific.

• Blocking Peptide Experiments: Using synthetic phosphopeptides corresponding to the Thr387 region can specifically block antibody binding. Some manufacturers offer blocking peptides specifically designed for this purpose . In a Western Blotting assay, the blocking peptide should prevent signal detection, confirming site-specificity.

• CHEK2 Knockdown/Knockout Controls: siRNA knockdown or CRISPR-mediated knockout of CHEK2 should eliminate the signal. This control helps distinguish specific from non-specific binding.

• Dominant-Negative CHEK2 Expression: As demonstrated in literature, expression of dominant-negative CHEK2 (Chk2DN) can block phosphorylation at Thr387 in response to DNA damage agents like bleomycin . This approach provides a functional validation of antibody specificity.

• Phosphorylation-Inducing Treatments: Treatment with DNA damaging agents (e.g., bleomycin, etoposide, or ionizing radiation) should increase phosphorylation at Thr387, providing a positive control for antibody function .

• Molecular Weight Verification: Phosphorylated CHEK2 should be detected at approximately 60-61 kDa by Western blot . Verification of this molecular weight helps confirm target specificity.

These validation strategies provide complementary evidence for antibody specificity and should ideally be combined for comprehensive validation.

What are the optimal experimental conditions for detecting CHEK2 phosphorylation at Thr387 in response to DNA damage?

Detecting CHEK2 phosphorylation at Thr387 in response to DNA damage requires careful optimization of experimental conditions:

• DNA Damage Induction:

  • Chemical agents: Bleomycin (10-20 μg/ml for 1-2 hours) effectively induces CHEK2 phosphorylation

  • Ionizing radiation: 5-10 Gy is typically sufficient

  • Topoisomerase inhibitors: Etoposide (10-20 μM for 2-4 hours)

• Timing considerations:

  • CHEK2 phosphorylation typically peaks 1-2 hours after acute DNA damage

  • For more persistent damage responses, monitor at multiple time points (1, 2, 4, 8, 24 hours)

• Sample preparation:

  • Rapid cell lysis is essential to preserve phosphorylation status

  • Include phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate) in all buffers

  • Maintain samples at 4°C throughout processing

• Western blotting optimization:

  • Use freshly prepared SDS-PAGE gels (8-10%) for optimal resolution

  • Transfer to PVDF membranes (rather than nitrocellulose) for better retention of phosphoproteins

  • Block with 5% BSA in TBST (not milk, which contains phosphatases)

  • Incubate with antibody at 4°C overnight for highest sensitivity

• Controls to include:

  • Untreated samples to establish baseline phosphorylation

  • Total CHEK2 antibody on parallel blots to normalize for expression variations

  • Positive control (e.g., HeLa cells treated with bleomycin)

These optimized conditions maximize the likelihood of detecting the dynamic phosphorylation of CHEK2 at Thr387 following DNA damage.

How can Cell-Based ELISA be used to quantitatively assess CHEK2 activation through Thr387 phosphorylation?

Cell-Based ELISA offers a powerful approach for quantitative assessment of CHEK2 Thr387 phosphorylation directly in cultured cells:

• Methodological approach:
  Cell-Based ELISA employs an indirect ELISA format where phosphorylated CHEK2 is captured by phospho-specific primary antibodies. HRP-conjugated secondary antibodies bind to the primary antibodies, enabling colorimetric detection upon substrate addition .

• Normalization strategies:
  Due to the qualitative nature of Cell-Based ELISA, multiple normalization methods should be employed:

  • Use of a monoclonal antibody against GAPDH as an internal positive control

  • Crystal Violet whole-cell staining to determine cell density, allowing normalization of absorbance values to cell numbers

• Experimental setup:

  • Plate cells in 96-well clear-bottom microplates (typically >5000 cells/well)

  • Include wells for:

    • Untreated controls

    • DNA damage-inducing agents

    • Potential inhibitors or activators

    • Secondary antibody-only controls to assess background

• Data analysis:

  • Calculate the ratio of phospho-CHEK2 to total CHEK2 signal

  • Normalize to GAPDH signal and/or Crystal Violet staining

  • Compare treated samples to untreated controls

• Applications:

  • Screening compounds that affect CHEK2 phosphorylation

  • Comparing CHEK2 activation across different cell lines

  • Measuring kinetics of CHEK2 phosphorylation in response to various stimuli

The Cell-Based ELISA approach provides advantages over traditional Western blotting, including higher throughput, reduced sample manipulation, and the ability to perform experiments directly in the cellular context without the need for cell lysis.

What experimental approaches can be used to study the functional significance of CHEK2 Thr387 phosphorylation?

Understanding the functional significance of CHEK2 Thr387 phosphorylation requires multi-faceted experimental approaches:

• Site-directed mutagenesis strategies:

  • Generate Thr387 to Ala (T387A) mutants to prevent phosphorylation

  • Create Thr387 to Glu (T387E) phosphomimetic mutants to simulate constitutive phosphorylation

  • Compare kinase activity, protein interactions, and cellular effects of these mutants

• Dominant-negative approaches:

  • Express dominant-negative CHEK2 (CHEK2DN) to block activation and downstream signaling

  • Monitor effects on cell cycle progression, DNA damage response, and cell survival

• Phosphorylation-specific protein interaction studies:

  • Perform co-immunoprecipitation using phospho-specific antibodies to identify proteins that interact specifically with phosphorylated CHEK2

  • Use techniques like BioID or proximity ligation assay (PLA) to identify phosphorylation-dependent interactions in situ

• Functional readouts:

  • Measure cell cycle checkpoint activation using flow cytometry

  • Assess DNA repair efficiency through comet assay or γH2AX foci formation/resolution

  • Evaluate apoptosis rates in response to DNA damage

  • Quantify senescence induction using SA-β-galactosidase staining

• Downstream substrate phosphorylation:

  • Monitor phosphorylation of known CHEK2 substrates (p53, BRCA1, CDC25C) in cells expressing wild-type versus mutant CHEK2

  • Correlate Thr387 phosphorylation with substrate phosphorylation kinetics

• Structural studies:

  • Use molecular dynamics simulations to model how Thr387 phosphorylation affects CHEK2 conformation

  • If possible, obtain crystal structures of phosphorylated versus non-phosphorylated CHEK2

These complementary approaches provide a comprehensive understanding of how Thr387 phosphorylation regulates CHEK2 function in DNA damage response pathways.

How does CHEK2 Thr387 phosphorylation coordinate with other phosphorylation sites during the DNA damage response?

CHEK2 activation involves a complex, hierarchical phosphorylation cascade with Thr387 playing a crucial role:

• Phosphorylation sequence in CHEK2 activation:

  • Initial phosphorylation at Thr68 by ATM kinase in response to DNA double-strand breaks

  • This promotes CHEK2 dimerization and autophosphorylation at multiple sites including:

    • Thr383

    • Thr387

    • Ser516

  • These autophosphorylation events are essential for full kinase activation

• Coordinated regulation:

  • Thr68 phosphorylation serves as the initiating event, dependent on ATM activation

  • Thr387 phosphorylation represents a subsequent step in activation, dependent on CHEK2's own kinase activity

  • This creates a feed-forward amplification loop that ensures robust CHEK2 activation

• Experimental approaches to study phosphorylation coordination:

  • Time-course experiments using site-specific phospho-antibodies to track the temporal sequence of phosphorylation events

  • Mutations at one phosphorylation site (e.g., T68A) to determine effects on other sites (e.g., Thr387)

  • Inhibitor studies using ATM inhibitors to block the initiating phosphorylation

• Technical considerations for multi-site phosphorylation analysis:

  • Use paired antibodies against different phosphorylation sites on the same Western blot

  • Consider multiplexed detection methods using differently labeled secondary antibodies

  • Use phosphoproteomic approaches to simultaneously monitor all phosphorylation sites

Understanding this coordinated regulation is essential for accurate interpretation of experimental results and for developing strategies to modulate CHEK2 activity in research or therapeutic contexts.

What are the best methodological approaches for studying CHEK2 Thr387 phosphorylation in cancer research?

Cancer research involving CHEK2 Thr387 phosphorylation requires specialized methodological approaches:

• Patient sample analysis:

  • Immunohistochemistry using phospho-specific antibodies on tissue microarrays from different cancer types

  • Correlation of Thr387 phosphorylation with clinical outcomes and genetic features

  • Consider dual staining with markers of DNA damage (γH2AX) or cell proliferation (Ki-67)

• Cancer cell line studies:

  • Comparison of basal and DNA damage-induced Thr387 phosphorylation across panels of cancer cell lines

  • Correlation with CHEK2 mutation status, p53 status, and DNA repair proficiency

  • Development of isogenic cell line pairs differing only in CHEK2 status

• Functional significance in cancer models:

  • Expression of T387A (phospho-dead) or T387E (phospho-mimetic) CHEK2 mutants in cancer cells

  • Assessment of effects on:

    • Chemotherapy and radiation sensitivity

    • Cell cycle checkpoint function

    • Genomic stability

    • Metastatic potential

• Connections to cancer-associated mutations:

  • Analysis of how cancer-associated CHEK2 mutations (especially those in Li-Fraumeni syndrome) affect Thr387 phosphorylation

  • Investigation of whether mutations in other genes affect CHEK2 Thr387 phosphorylation

• Therapeutic implications:

  • Use of Thr387 phosphorylation as a biomarker for DNA-damaging therapy response

  • Development of screening assays to identify compounds that modulate CHEK2 phosphorylation

• Animal model approaches:

  • Generation of knock-in mouse models with T387A or T387E mutations

  • Analysis of tumor development and response to DNA damage in these models

These methodological approaches enable researchers to investigate the complex role of CHEK2 Thr387 phosphorylation in cancer development, progression, and treatment response, potentially leading to new diagnostic or therapeutic strategies.

What are the critical considerations for troubleshooting Western blot detection of phosphorylated CHEK2 (Thr387)?

When troubleshooting Western blot detection of phosphorylated CHEK2 (Thr387), consider these critical factors:

• Sample preparation optimization:

  • Rapid harvesting and processing to prevent dephosphorylation

  • Use of strong phosphatase inhibitor cocktails in all buffers

  • Avoidance of multiple freeze-thaw cycles that can degrade phosphoproteins

• Detection challenges and solutions:

  • Low signal issue: Optimize antibody concentration (try 1:500 dilution), extend incubation time to overnight at 4°C

  • High background: More stringent washing (5-6 times, 10 minutes each), optimize blocking (try 5% BSA instead of milk)

  • Non-specific bands: Confirm molecular weight (60-61 kDa) , use blocking peptides to verify specificity

  • Inconsistent results: Standardize DNA damage treatment conditions, control cell confluence

• Technical considerations:

  • Use freshly prepared reducing agents in sample buffer

  • Consider gradient gels (4-15%) for better resolution

  • Wet transfer systems may preserve phosphoepitopes better than semi-dry

  • For challenging detections, enhance sensitivity with amplified detection systems

• Controls to implement:

  • Positive control: HeLa cells treated with bleomycin consistently show Thr387 phosphorylation

  • Negative control: Samples treated with lambda phosphatase

  • Loading control: Reprobe for total CHEK2 or housekeeping proteins

  • Expression control: If working with transfected CHEK2, confirm expression with tag-specific antibodies

• Common artifacts to be aware of:

  • In cells expressing dominant-negative CHEK2, a faster migrating form might be detected by Thr387 antibody, representing basal phosphorylation

  • Heterogeneous expression in pooled cultures may result in variable phosphorylation levels

Addressing these considerations systematically can significantly improve detection of phosphorylated CHEK2 (Thr387) by Western blotting.

How can I optimize immunofluorescence procedures for detecting phosphorylated CHEK2 (Thr387) in different cell types?

Optimizing immunofluorescence for phosphorylated CHEK2 (Thr387) requires careful attention to multiple experimental parameters:

• Fixation and permeabilization optimization:

  • Fixation: 4% paraformaldehyde (10-15 minutes) preserves phosphoepitopes better than methanol

  • Permeabilization: Test both 0.1% Triton X-100 and 0.5% saponin to determine optimal access to nuclear proteins

  • Critical step: Include phosphatase inhibitors (10 mM NaF, 1 mM Na₃VO₄) in all buffers to preserve phosphorylation

• Antibody incubation parameters:

  • Dilution range: Start with 1:100 dilution and optimize as needed (1:50-1:200 is typical)

  • Incubation time: Overnight at 4°C generally provides better signal-to-noise ratio than shorter incubations

  • Blocking: Use 3-5% BSA with 10% normal serum from secondary antibody host species

• Cell type-specific considerations:

  • Cancer cell lines: May have higher basal phosphorylation; consider shorter DNA damage treatments

  • Primary cells: May require stronger DNA damage stimuli; optimize cell density for consistent results

  • Tissues: May require antigen retrieval methods (citrate buffer pH 6.0 or EDTA buffer pH 9.0)

• Signal enhancement strategies:

  • Tyramide signal amplification for weak signals

  • Use of highly cross-adsorbed secondary antibodies to minimize background

  • Consider super-resolution microscopy techniques for detailed localization studies

• Co-staining approaches:

  • Double-stain with total CHEK2 antibody (from different host species) to normalize phospho-signal

  • Co-stain with DNA damage markers (γH2AX) to correlate with DNA lesions

  • Nuclear counterstaining with DAPI to assess nuclear localization

• Controls and quantification:

  • Untreated versus DNA damage-treated cells as negative/positive controls

  • Secondary antibody-only controls to assess background

  • Quantitative image analysis using software like ImageJ/FIJI with consistent thresholding

Following these optimization steps will help achieve reliable and reproducible immunofluorescence detection of phosphorylated CHEK2 (Thr387) across different experimental systems.